291 related articles for article (PubMed ID: 37326116)
21. FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson's disease: A whole-brain multimodal imaging meta-analysis.
Albrecht F; Ballarini T; Neumann J; Schroeter ML
Neuroimage Clin; 2019; 21():101594. PubMed ID: 30514656
[TBL] [Abstract][Full Text] [Related]
22. The role of neuroimaging in Parkinson's disease.
Bidesi NSR; Vang Andersen I; Windhorst AD; Shalgunov V; Herth MM
J Neurochem; 2021 Nov; 159(4):660-689. PubMed ID: 34532856
[TBL] [Abstract][Full Text] [Related]
23. Neuroimaging approaches to cognition in Parkinson's disease.
Montaser-Kouhsari L; Young CB; Poston KL
Prog Brain Res; 2022; 269(1):257-286. PubMed ID: 35248197
[TBL] [Abstract][Full Text] [Related]
24. Neural Correlates of Cognitive Impairment in Parkinson's Disease: A Review of Structural MRI Findings.
Hall JM; Lewis SJG
Int Rev Neurobiol; 2019; 144():1-28. PubMed ID: 30638452
[TBL] [Abstract][Full Text] [Related]
25. Neuroimaging correlates of cognitive impairment and dementia in Parkinson's disease.
Mak E; Su L; Williams GB; O'Brien JT
Parkinsonism Relat Disord; 2015 Aug; 21(8):862-70. PubMed ID: 26004683
[TBL] [Abstract][Full Text] [Related]
26. Brain plasticity in Parkinson's disease with freezing of gait induced by action observation training.
Agosta F; Gatti R; Sarasso E; Volonté MA; Canu E; Meani A; Sarro L; Copetti M; Cattrysse E; Kerckhofs E; Comi G; Falini A; Filippi M
J Neurol; 2017 Jan; 264(1):88-101. PubMed ID: 27778161
[TBL] [Abstract][Full Text] [Related]
27. Current Perspectives on Aerobic Exercise in People with Parkinson's Disease.
Schootemeijer S; van der Kolk NM; Bloem BR; de Vries NM
Neurotherapeutics; 2020 Oct; 17(4):1418-1433. PubMed ID: 32808252
[TBL] [Abstract][Full Text] [Related]
28. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease.
Petzinger GM; Fisher BE; McEwen S; Beeler JA; Walsh JP; Jakowec MW
Lancet Neurol; 2013 Jul; 12(7):716-26. PubMed ID: 23769598
[TBL] [Abstract][Full Text] [Related]
29. Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.
Conrado DJ; Nicholas T; Tsai K; Macha S; Sinha V; Stone J; Corrigan B; Bani M; Muglia P; Watson IA; Kern VD; Sheveleva E; Marek K; Stephenson DT; Romero K;
Clin Transl Sci; 2018 Jan; 11(1):63-70. PubMed ID: 28749580
[TBL] [Abstract][Full Text] [Related]
30. The EXPANd trial: effects of exercise and exploring neuroplastic changes in people with Parkinson's disease: a study protocol for a double-blinded randomized controlled trial.
Franzén E; Johansson H; Freidle M; Ekman U; Wallén MB; Schalling E; Lebedev A; Lövdén M; Holmin S; Svenningsson P; Hagströmer M
BMC Neurol; 2019 Nov; 19(1):280. PubMed ID: 31718583
[TBL] [Abstract][Full Text] [Related]
31. Towards understanding neural network signatures of motor skill learning in Parkinson's disease and healthy aging.
Nackaerts E; D'Cruz N; Dijkstra BW; Gilat M; Kramer T; Nieuwboer A
Br J Radiol; 2019 Sep; 92(1101):20190071. PubMed ID: 30982328
[TBL] [Abstract][Full Text] [Related]
32. Prevention of Parkinson's Disease: From Risk Factors to Early Interventions.
Ng MG; Chan BJL; Koh RY; Ng KY; Chye SM
CNS Neurol Disord Drug Targets; 2024; 23(6):746-760. PubMed ID: 37326115
[TBL] [Abstract][Full Text] [Related]
33. Neuroimaging: current role in detecting pre-motor Parkinson's disease.
Godau J; Hussl A; Lolekha P; Stoessl AJ; Seppi K
Mov Disord; 2012 Apr; 27(5):634-43. PubMed ID: 22508281
[TBL] [Abstract][Full Text] [Related]
34. Neuroimaging advances in Parkinson's disease with freezing of gait: A systematic review.
Bharti K; Suppa A; Tommasin S; Zampogna A; Pietracupa S; Berardelli A; Pantano P
Neuroimage Clin; 2019; 24():102059. PubMed ID: 31795038
[TBL] [Abstract][Full Text] [Related]
35. Premorbid exercise engagement and motor reserve in Parkinson's disease.
Sunwoo MK; Lee JE; Hong JY; Ye BS; Lee HS; Oh JS; Kim JS; Lee PH; Sohn YH
Parkinsonism Relat Disord; 2017 Jan; 34():49-53. PubMed ID: 27852513
[TBL] [Abstract][Full Text] [Related]
36. GLP-1 receptor agonists for Parkinson's disease.
Mulvaney CA; Duarte GS; Handley J; Evans DJ; Menon S; Wyse R; Emsley HC
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012990. PubMed ID: 32700772
[TBL] [Abstract][Full Text] [Related]
37. Evidence Supports PA Prescription for Parkinson's Disease: Motor Symptoms and Non-Motor Features: A Scoping Review.
Cheng YC; Su CH
Int J Environ Res Public Health; 2020 Apr; 17(8):. PubMed ID: 32331349
[TBL] [Abstract][Full Text] [Related]
38. PD and DLB: Brain imaging in Parkinson's disease and dementia with Lewy bodies.
Berman SB; Miller-Patterson C
Prog Mol Biol Transl Sci; 2019; 165():167-185. PubMed ID: 31481162
[TBL] [Abstract][Full Text] [Related]
39. A clinical-anatomical signature of Parkinson's disease identified with partial least squares and magnetic resonance imaging.
Zeighami Y; Fereshtehnejad SM; Dadar M; Collins DL; Postuma RB; Mišić B; Dagher A
Neuroimage; 2019 Apr; 190():69-78. PubMed ID: 29277406
[TBL] [Abstract][Full Text] [Related]
40. Sex effects on brain structure in de novo Parkinson's disease: a multimodal neuroimaging study.
Tremblay C; Abbasi N; Zeighami Y; Yau Y; Dadar M; Rahayel S; Dagher A
Brain; 2020 Oct; 143(10):3052-3066. PubMed ID: 32980872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
